AAAAAA
Results:
1-7
|
Results: 7
Authors:
Stringer, KA
Lopez, L
Talbert, RL
Citation: Ka. Stringer et al., A call for pharmacists to improve the care of patients with myocardial infarction, PHARMACOTHE, 21(11), 2001, pp. 1317-1319
Authors:
Sherman, DS
Clarke, SH
Lefkowitz, JB
Valuck, RJ
Lindenfeld, J
Stringer, KA
Citation: Ds. Sherman et al., An institution-specific heparin titration nomogram: Development, validation, and assessment of compliance, PHARMACOTHE, 21(10), 2001, pp. 1167-1174
Authors:
Stringer, KA
Citation: Ka. Stringer, Tissue plasminogen activator inhibits reactive oxygen species production by macrophages, PHARMACOTHE, 20(4), 2000, pp. 375-379
Authors:
Stratton, MA
Anderson, FA
Bussey, HI
Caprini, J
Comerota, A
Haines, ST
Hawkins, DW
O'Connell, MB
Smith, RC
Stringer, KA
Citation: Ma. Stratton et al., Prevention of venous thromboembolism - Adherence to the 1995 American College of Chest Physicians consensus guidelines for surgical patients, ARCH IN MED, 160(3), 2000, pp. 334-340
Authors:
Stringer, KA
Citation: Ka. Stringer, The evolving role of platelet glycoprotein IIb IIIa inhibitors in the management of acute coronary syndromes, ANN PHARMAC, 33(6), 1999, pp. 712-722
Authors:
Stringer, KA
Citation: Ka. Stringer, Advances in the treatment of acute coronary syndromes: Focus on low-molecular-weight heparins - Introduction, PHARMACOTHE, 19(9), 1999, pp. 139S-140S
Authors:
Stringer, KA
Citation: Ka. Stringer, Emergence of low-molecular-weight heparins in cardiology, PHARMACOTHE, 19(9), 1999, pp. 141S-146S
Risultati:
1-7
|